Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04792645 · ClinicalTrials.gov registry record · Phase 2
Memantine in Body Focused Repetitive Behaviors
A Phase 2 study of Trichotillomania (Hair-Pulling Disorder) and Dermatillomania, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04792645: Completed Phase 2 study of Trichotillomania (Hair-Pulling Disorder) and Dermatillomania, sponsored by University of Chicago.
NCT04792645 is a Phase 2 study of Trichotillomania (Hair-Pulling Disorder) and Dermatillomania that has completed, run by University of Chicago. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04792645, a Phase 2 study of Trichotillomania (Hair-Pulling Disorder) and Dermatillomania, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is 8 weeks long and involves subjects taking memantine or placebo. If they are randomly assigned to the memantine arm and are eligible to participate in the study, they will begin by taking 10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks. Efficacy and safety measures will be performed at each visit. Participants will be randomized to receive either memantine or placebo on a 1:1 basis. This blinding will be maintained by the IDS pharmacy at the University of Chicago.
Primary Outcome
The primary efficacy measure will be the change in hair pulling or skin picking frequency and urges to pull hair or pick skin for the past week as indicated by change in total score. The entire study lasts 10 weeks. Every two weeks subjects will take the NIMH Symptom Severity Scale. The change in scores from baseline to after 8 weeks will be assessed. The scale itself assesses severity of trichotillomania or skin picking symptom, with higher scores indicating greater trichotillomania or skin pic
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Memantine
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-06-15 |
| Est. Completion | 2022-07-08 |
| Phase | Phase 2 |
What the finished NCT04792645 record still lists
NCT04792645 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 2 conditions, with Trichotillomania (Hair-Pulling Disorder) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04792645 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04792645 about?
NCT04792645 is a clinical study titled "Memantine in Body Focused Repetitive Behaviors". This study is 8 weeks long and involves subjects taking memantine or placebo. If they are randomly assigned to the memantine arm and are eligible to participate in the study, they will begin by taking 10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks. Efficacy and saf...
What is the current status of trial NCT04792645?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2021-06-15. Estimated completion is 2022-07-08.
What conditions does trial NCT04792645 study?
This clinical trial studies the following conditions: Trichotillomania (Hair-Pulling Disorder), Dermatillomania.
What interventions are being tested in trial NCT04792645?
The interventions under investigation include: Placebo (DRUG), Memantine (DRUG).
Who is sponsoring clinical trial NCT04792645?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04792645 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trichotillomania (Hair-Pulling Disorder)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04792645's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI